We have located links that may give you full text access.
A potential prognostic prediction model for metastatic osteosarcoma based on bioinformatics analysis.
Acta Orthopaedica Belgica 2023 September
Osteosarcoma (OS) is a malignant primary bone tumor with a high incidence. This study aims to construct a prognostic prediction model by screening the prognostic mRNA of metastatic OS. Data on four eligible expression profiles from the National Center for Biotechnology Information Gene Expression Omnibus repository were obtained based on inclusion criteria and defined as the training set or the validation set. The differentially expressed genres (DEGs) between meta- static and non-metastatic OS samples in the training set were first identified, and DEGs related to prognosis were screened by univariate Cox regression analysis. In total, 107 DEGs related to the prognosis of metastatic OS were identified. Then, 46 DEGs were isolated as the optimized prognostic gene signature, and a metastatic-OS discriminating classifier was constructed, which had a high accuracy in distinguishing metastatic from non-metastatic OS samples. Furthermore, four optimized prognostic gene signatures (ALOX5AP, COL21A1, HLA-DQB1, and LDHB) were further screened, and the prognostic prediction model for metastatic OS was constructed. This model possesses a relatively satisfying prediction ability both in the training set and validation set. The prognostic prediction model that was constructed based on the four prognostic mRNA signatures has a high predictive ability for the prognosis of metastatic OS.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app